Viking Therapeutics Inc (NASDAQ:VKTX) has received an average recommendation of “Buy” from the nine research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $28.17.
A number of equities research analysts recently weighed in on the company. Raymond James set a $43.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 19th. SunTrust Banks lifted their target price on Viking Therapeutics to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, September 19th. Roth Capital lifted their price objective on Viking Therapeutics from $13.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, September 19th. Maxim Group reaffirmed a “buy” rating and set a $28.00 price objective (up from $14.00) on shares of Viking Therapeutics in a report on Tuesday, September 18th. Finally, HC Wainwright set a $28.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 18th.
In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $19.15, for a total transaction of $5,034,171.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is currently owned by insiders.
VKTX stock traded up $0.99 during trading on Tuesday, reaching $14.29. 3,926,333 shares of the stock were exchanged, compared to its average volume of 3,703,867. Viking Therapeutics has a twelve month low of $2.08 and a twelve month high of $24.00. The company has a market cap of $866.80 million, a PE ratio of -18.09 and a beta of 2.82.
Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts predict that Viking Therapeutics will post -0.44 EPS for the current fiscal year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Recommended Story: Google Finance
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.